MANA Advisors LLC purchased a new stake in Opko Health Inc. (NASDAQ:OPK) during the fourth quarter, Holdings Channel reports. The fund purchased 78,845 shares of the biotechnology company’s stock, valued at approximately $386,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Crossmark Global Holdings Inc. bought a new stake in shares of Opko Health in the 3rd quarter worth about $118,000. State of Alaska Department of Revenue bought a new stake in shares of Opko Health in the 4th quarter worth about $144,000. The Manufacturers Life Insurance Company increased its holdings in shares of Opko Health by 7.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,657 shares during the last quarter. First Trust Advisors LP bought a new stake in shares of Opko Health in the 4th quarter worth about $154,000. Finally, ING Groep NV increased its holdings in shares of Opko Health by 121.2% in the 4th quarter. ING Groep NV now owns 71,168 shares of the biotechnology company’s stock worth $349,000 after buying an additional 39,000 shares during the last quarter. Institutional investors own 23.40% of the company’s stock.
In other news, CEO Phillip Md Et Al Frost purchased 75,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 7th. The stock was purchased at an average cost of $3.29 per share, with a total value of $246,750.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $10,096,848.79. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders have purchased 1,306,300 shares of company stock valued at $4,935,197. 40.19% of the stock is owned by corporate insiders.
A number of research firms have recently weighed in on OPK. BidaskClub downgraded shares of Opko Health from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 10th. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a report on Friday, February 9th. JPMorgan Chase & Co. downgraded shares of Opko Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price on the stock. in a report on Friday, March 2nd. Finally, ValuEngine downgraded shares of Opko Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Four investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Opko Health has an average rating of “Hold” and a consensus price target of $13.25.
TRADEMARK VIOLATION WARNING: This news story was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.themarketsdaily.com/2018/03/12/mana-advisors-llc-purchases-new-holdings-in-opko-health-inc-opk.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NASDAQ:OPK).
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.